On the heels of the FDA approval of Celltrion’s rituximab biosimilar Truxima in November 2018, December saw the publication of a variety of new data on biosimilars used in hematology.
On the heels of the FDA approval of Celltrion’s rituximab biosimilarTruxima in November 2018, December saw the publication of a variety of new data on biosimilars used in hematology.
Much of those data were derived from this month’s American Society of Hematology’s 60th Annual Meeting & Exposition, held from the first to the fourth of the month in San Diego, California, during which several research teams presented fresh findings that underscore the benefits of biosimilars.
A number of those research teams focused on granulocyte colony-stimulating factor (G-CSF) therapies. First, assessing data from the Saskatchewan Cancer Agency, which switched to using Apotex’s filgrastim biosimilar, Grastofil, for stem cell mobilization prior to autologous stem cell transplants (ASCT) in 2016, researchers found that, when using either the biosimilar or the reference Neupogen before ASCT, each medication has similar efficacy. The authors concluded that prescribing the biosimilar over the reference product could provide substantial savings.
Another team found that, among patients undergoing transplantation who were receiving Zarxio or the reference filgrastim, there was no difference in plerixafor use between the 2 groups. Given that the cost of the biosimilar was approximately 50% lower than that of the reference product, using the biosimilar G-CSF agent once again provided an opportunity for significant cost savings.
Biosimilar filgrastim was shown to generate substantial cost savings over reference pegfilgrastim in its on-body injector presentation. In a simulation analysis from the payer perspective, researchers concluded that the incremental costs of delivering pegfilgrastim via on-body device for febrile neutropenia (FN) prophylaxis was lowest when compared with regular pegfilgrastim, and highest when compared with biosimilar filgrastim, at a real-world duration of 5 days.
A follow-on filgrastim, tbo-filgrastim (Granix) was demonstrated to provide the greatest cost-savings for the Veterans Health Administration, beating both Zarxio and the reference filgrastim on savings realized. However, switching patients to tbo-filgrastim from the brand-name option provided only a modest savings—just 2.2%—under 340B pricing. According to researchers, other approaches to reducing the cost of G-CSF therapy are likely to have a greater impact on the overall cost of care than a switch to biosimilars, including:
Despite findings showing that biosimilars can curb costs, concerns remain about the slow pace of US biosimilar uptake for the prophylaxis of FN. Writing in JAMA Oncology, a team of authors pointed to the current lack of interchangeability, patent litigation, and rebates as culprits for low uptake. Writing in The Center for Biosimilars®, contributor Isha Bangia, PharmD, MBA, highlighted the payer’s role in the sluggish pace of biosimilar adoption.
Among rituximab biosimilars, the newly approved Truxima was shown in several studies to be safe and effective in treating a variety of hematological diseases. First, UK researchers reported that the reference and biosimilar rituximab demonstrated equivalence in treating patients with immune thrombotic thrombocytopenic purpura, and that the mean savings to the healthcare system per patient treated with the biosimilar was £4000 (approximately $5089). Second, results from the first 7 months of a phase 3 study in patients with previously untreated follicular lymphoma (FL) with low tumor burden demonstrated that Truxima and the reference rituximab had therapeutic equivalence. Finally, a study in patients with previously untreated advanced FL showed that, at 23 months, treatment with Truxima or its reference led to comparable progression-free survival.
Additionally, PF-05280586, a proposed rituximab developed by Pfizer, got a boost from new data that showed that the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of PF-05280586 and the reference rituximab were similar at 26 weeks in patients with previously untreated CD20-positive FL with low tumor burden.
Industry appears to expect substantial sales from Pfizer’s product; Vantage’s annual preview of the pharmaceuticals market predicted that, in 2019, the proposed rituximab biosimilar for which a regulatory decision is expected in the third quarter of the year will be among the most valuable research and development projects of the year. The proposed biosimilar has a net present value of $3.6 billion, Vantage said.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.